Wholly Owned Pipeline

PureTech's Wholly Owned Pipeline is focused on the lymphatic system and related immunology mechanisms for the treatment of cancer and immunological, lymphatic and CNS-related disorders. 

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Initiation of POC study in 2020

1

Lymphatic flow disorders, incl. lymphedema

~1M

Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-100
Deupirfenidone
COVID-19 post-recovery respiratory complications
Initiation of POC study in Q3 2020

1

COVID-19 post-recovery respiratory complications


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders

1

Other fibrotic & inflammatory disorders

~130K (IPF or uILD)


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND and initiation of Ph1a/1b study in 2020

Preclinical

Solid tumors

57K/year (Pancreatic cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers, such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

57K/year (Pancreatic Cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

LYT-210
Anti-Delta-1 MAb
GI autoimmunity

Preclinical

GI autoimmunity

57K/year (Pancreatic Cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

Lymphatic Targeting Chemistry Platform
Orphan & other
neurological indications

A synthetic lymphatic targeting chemistry platform being developed to employ the body’s natural lipid absorption and transport process to orally administer drugs via the lymphatic system by (1) targeting the mesenteric lymph nodes and (2) bypassing first-pass metabolism.

Milk Exosome Platform

A milk exosome-based technology being developed to enable oral administration of macromolecule therapeutic payloads, including antisense oligonucleotides, short interfering RNA, messenger RNA (mRNA), peptides and nanoparticles that are otherwise administered exclusively by injection.

Meningeal Lymphatics Platform

A platform that aims to correct lymphatic dysfunction in the brain to potentially improve outcomes for a range of neurodegenerative and neuroinflammatory conditions that are not currently effectively treated, such as Alzheimer’s disease and Parkinson’s disease.

Phase completedPhase in progress

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with multiple major pharma companies or their investment arms